UPUlrich W. Preuss

Ulrich W. Preuss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ulrich W. Preuss has a total of 176 co-authors. Here are the top co-authors by number of shared publications:

  • G. Koller

    Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University, Nussbaumstrasse 7, D-80336 Munich, Germany

    5 shared publications
  • Michael Soyka

    Department of Otorhinolaryngology Head and Neck Surgery University Hospital Zürich, University of Zürich Zürich Switzerland

    5 shared publications
  • C. Fehr

    Department of Psychiatry, Johannes-Gutenberg-University, Mainz, Germany

    4 shared publications
  • M. Soyka

    Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University, Nussbaumstrasse 7, D-80336 Munich, Germany

    4 shared publications
  • Michael Soyka

    Department of Psychiatry, Ludwig Maximilian University, München, Germany Privatklinik Meiringen, Meiringen, Switzerland

    4 shared publications
  • S. Watzke

    Department of Psychiatry, Psychotherapy and Psychosomatics,University of Halle-Wittenberg,Germany

    4 shared publications

Latest Publications

  • Synthetische Cannabinoide: eine narrative Übersicht

    by Ulrich W. Preuss, Eva M. Hoch

    Zusammenfassung: Die seit einigen Jahren verfügbaren synthetischen Cannabinoiden (SC) zählen zu den NPS (neue psychoaktive Substanzen). Bei SC handelt es sich um eine sehr heterogene Gruppe von Substanzen mit häufig stark agonistischer Wirkung auf Cannabisrezeptoren, die beim Konsum vielfältige, zum Teil gesundheitsgefährdende Wirkungen auslösen können. Die SC gelten als die am häufigsten konsumierten NPS. Ziel dieser narrativen Übersicht ist es, aktuelle Kenntnisse hinsichtlich Pharmakologie, Epidemiologie, Wirkungen, Diagnostik und Risiko von Konsumstörungen sowie Behandlungsansätzen darzustellen.

  • Corona-Krise: Wie ist die Situation des Suchthilfesystems danach?

    by Ulrich W. Preuss

    Liebe Leserinnen und Leser: die Corona-Pandemie hat das Leben aller und auch von Patienten mit Alkohol- und Substanzkonsumstörungen deutlich verändert. Mit ihr gingen zahlreiche Einschränkungen und Veränderungen einher. Besonders schwer getroffen wurden diejenigen, die ohnehin schon mit Abhängigkeiten zu kämpfen hatten. Ein besonders dramatisches Beispiel ist der Fall eines alkoholabhängigen Patienten, der jahrelang trocken war und von einem gut funktionierenden Netzwerk aus Selbsthilfegruppe und Suchtberatungsstelle unterstützt wurde.

  • Open Access

    A Prospective Comparison of Bipolar I and II Subjects with and without Comorbid Cannabis Use Disorders from the COGA Dataset

    by Ulrich W. Preuss, Michie N. Hesselbrock, Victor M. Hesselbrock

    Objective: The comorbidity of alcohol and substance use disorders among persons with bipolar disorder is elevated, as indicated by epidemiological and clinical studies. Following alcohol use, cannabis is the most frequently used and abused illicit substance among bipolar individuals, and such use may lead to comorbid cannabis use disorders (CUD). Previous research indicated that CUDs were related to a more severe course of bipolar disorder and higher rates of other comorbid alcohol and substance use disorders. Few studies, however, have conducted longitudinal research on this comorbidity. The aim of this study is to investigate the influence of CUD on the course of bipolar I and II individuals during a 5-year follow-up. Methods: The characteristics of bipolar disorder, cannabis use disorders, and other alcohol and substance use disorders, as well as comorbid mental disorders, were assessed using a standardized semi-structured interview (SSAGA) at both baseline and the 5-year follow-up. N = 180 bipolar I and II patients were subdivided into groups of with and without comorbid cannabis use disorders (CUD). Results: Of the 77 bipolar I and 103 bipolar II patients, n = 65 (36.1%) had a comorbid diagnosis of any CUD (DSM-IV cannabis abuse or dependence). Comorbid bipolar patients with CUD had higher rates of other substance use disorders and posttraumatic stress disorders, more affective symptoms, and less psychosocial functioning at baseline and at 5-year follow-up. In contrast to previously reported findings, higher rates of anxiety disorders and bipolar disorder complications (e.g., mixed episodes, rapid cycling, and manic or hypomanic episodes) were not found. The effect of CUD on other substance use disorders was confirmed using moderation analyses. Conclusions: A 5-year prospective evaluation of bipolar patients with and without CUD confirmed previous investigations, suggesting that the risk of other substance use disorders is significantly increased in comorbid individuals. CUD has a moderation effect, while no effect was found for other mental disorders. Findings from this study and previous research may be due to the examination of different phenotypes (Cannabis use vs. CUD) and sample variation (family study vs. clinical and epidemiological populations).


  • Open Access

    Prospective DNA Methylation Analysis of the CpG GABRA2 Receptor Subunit in Alcohol Dependence during Detoxification

    by Ulrich W. Preuss, Gabriele Koller, Peter Zill

    Background and Objectives: Variants of GABRA2 have been repeatedly associated with alcohol dependence risk. However, no study investigated potential epigenetic alterations in the GABRA2 gene in alcohol-dependent (AD) subjects during alcohol withdrawal. We investigated DNA methylation pattern in the regulatory region of GABRA2 gene in peripheral leukocytes of AD patients and controls. Further, GABRA2 methylation patterns were analysed in neuroblastoma cells under ethanol exposure and withdrawal. Materials and Methods: In the present study, blood samples were obtained from 41 AD subjects on the day of inpatient admission, after the first and second week of inpatient treatment. The comparison group included 47 healthy controls. GABRA2 methylation of 4 CpG sites in the CpG island was compared to neuroblastoma cells which were exposed to 100 mM of ethanol for 2, 5 and 9 days, followed by a withdrawal interval of 4 days. Results: no significant differences in GABRA2 methylation patterns were found in AD subjects over time and vs. controls, after controlling for age. Further, no influence of withdrawal severity, alcohol consumption before admission and other alcohol dependence characteristics were found. Conclusions: The results indicate that GABRA2 methylation in AD individuals and in a cell model is unaffected by alcohol exposition and withdrawal. Influences of GABRA2 on characteristics of alcohol dependence may be exerted by mechanisms other than epigenetic alterations related to alcohol intoxication or withdrawal.


  • Open Access

    Cannabis Use and Car Crashes: A Review

    by Ulrich W. Preuss, Marilyn A. Huestis, Miriam Schneider, Derik Hermann, Beat Lutz, Alkomiet Hasan, Joseph Kambeitz, Jessica W. M. Wong, Eva Hoch

    In this review, state-of-the-art evidence on the relationship between cannabis use, traffic crash risks, and driving safety were analyzed. Systematic reviews, meta-analyses, and other relevant papers published within the last decade were systematically searched and synthesized. Findings show that meta-analyses and culpability studies consistently indicate a slightly but significantly increased risk of crashes after acute cannabis use. These risks vary across included study type, crash severity, and method of substance application and measurement. Some studies show a significant correlation between high THC blood concentrations and car crash risk. Most studies do not support this relationship at lower THC concentrations. However, no scientifically supported clear cut-off concentration can be derived from these results. Further research is needed to determine dose-response effects on driving skills combined with measures of neuropsychological functioning related to driving skills and crash risk.


  • Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines

    by U. W. Preuss, E. Gouzoulis-Mayfrank, U. Havemann-Reinecke, I. Schäfer, M. Beutel, E. Hoch, K. F. Mann

    Alcohol use disorders (AUD) have a high comorbidity with mental disorders. Vice versa, alcohol consumption plays an important role in affective disorders, anxiety disorders, ADHD, schizophrenic psychosis, and other mental disorders. In developing the current interdisciplinary, evidence-based treatment guideline on screening, diagnostics, and treatment of AUD, available research on comorbid mental diseases in AUD has been compiled to generate recommendations for treatment. The guideline was prepared under the responsibility of the German Association for Psychiatry, Psychotherapy, and Psychosomatics (DGPPN) and the German Association for Addiction Research and Therapy (DG-Sucht). To meet the methodological criteria for the highest quality guidelines (“S3-criteria”) as defined by the Association of Scientific Medical Societies in Germany (AWMF), the following criteria were employed: (1) a systematic search, selection, and appraisal of the international literature; (2) a structured process to reach consensus; and (3) inclusion of all relevant representatives of future guideline users. After assessing and grading the available literature, the expert groups generated several recommendations for the screening, diagnosis, and treatment of comorbid mental disorders. These recommendations were subdivided into psycho-, pharmaco-, and combination therapies. These are the first guidelines ever to make specific treatment recommendations for comorbid mental diseases in AUD. The recommendations extend to different treatment approaches including diagnostics and settings to present available effective and state-of-the-art treatment approaches to clinicians. Hitherto, many clinical constellations have not been addressed in research. Therefore, recommendations for future research are specified.


  • Komorbidität affektiver Erkrankungen und alkoholbezogener Störungen

    by J. W. M. Wong, E. Hoch, U. W. Preuss

    Psychische Erkrankungen und Alkoholkonsumstörungen sind häufig komorbid. Die aktuell gültigen S3-Leitlinien zu alkoholbezogenen Störungen fassen die Studienlage bis 2012 zusammen und entwickelt evidenzbasiert abgeleitete Empfehlungen für die klinische Praxis. Ziel dieses Beitrages ist es, die Ergebnisse der S3-Leitlinienentwicklung zur Komorbidität mit affektiven Erkrankungen und alkoholbezogenen Störungen zusammen zu fassen und aktuelle Studien aus den Folgejahren zu berücksichtigen. Die Entwicklungen in Epidemiologie, Psycho- und Pharmakotherapie sowie der Einsatz von digitalen oder internetbasierten Verfahren wird dargestellt. Alcohol-related disorders have a high comorbidity with mental disorders. In currently available S3 guidelines on alcohol use disorders include RCT and studies between the years 2005 and 2012. Evidence-based recommendations were developed for clinical practice. The aim of this paper is to update the S3 guideline studies and to include recent research during the last years. This recent current research includes results from epidemiological, psychotherapy and psychopharmacological studies. Studies on digital and internet-based approaches are presented too.

  • Psychische Komorbiditäten bei alkoholbedingten Störungen

    by U.W. Preuss, E. Gouzoulis-Mayfrank, U. Havemann-Reinecke, I. Schäfer, M. Beutel, K.F. Mann, E. Hoch

    Die Rate komorbider psychischer Erkrankungen ist bei alkoholbezogenen Störungen hoch. Umgekehrt spielen Alkoholkonsumstörungen bei affektiven und Angsterkrankungen sowie schizophrenen Psychosen eine wichtige Rolle hinsichtlich des Krankheitsverlaufes. Im Rahmen der aktuellen S3-Leitlinienentwicklung wurde evidenzbasiertes Wissen zur Häufigkeit und Bedeutung komorbider Störungen bei Alkoholabhängigen zusammengestellt und es wurden Behandlungsempfehlungen erstellt. Für die Erstellung der Leitlinie wurden ausgehend von spezifischen Fragestellungen bereits existierende Leitlinien aus verschiedenen Ländern und systematische Literaturrecherchen berücksichtigt. Diese wurden nach Evidenzgrad bewertet und daraus Empfehlungen abgeleitet. Evidenz und Empfehlungen gliedern sich in Abschnitte zur Psycho-, Pharmako- und Kombinationstherapie, die jeweils differenziell auf die Wirksamkeit auf psychische Symptome und Trinkverhalten unterscheiden. Darüber hinaus wurde für affektive Störungen ein Behandlungspfad für das schrittweise Vorgehen bei beiden Komorbiditäten entwickelt. Erstmals wurden im Rahmen einer Leitlinie Behandlungsempfehlungen für komorbide psychische Erkrankungen bei alkoholbezogenen Störungen differenziert erarbeitet. Diese erstrecken sich auf verschiedene Therapieansätze, schließen auch Diagnostik und Settingbedingungen ein und ermöglichen dem Kliniker eine praxisnahe Berücksichtigung.